Analyst Reco. eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.89 ^USD	+4.42%		+11.18%	-83.83%

Apr. 04	Health Care Down on Retreat From Risk -- Health Care Roundup	DJ
Apr. 04	Top Midday Decliners	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	23-08-24	MT
Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	23-05-26	MT
Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	23-05-10	MT
Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	23-03-09	MT
JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	23-01-09	MT
Credit Suisse Lowers eFFECTOR Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating	23-01-06	MT
JMP Securities Trims Price Target on eFFECTOR Therapeutics to $2 From $5, Maintains Market Outperform Rating	22-11-17	MT
JMP Securities Lowers eFFECTOR Therapeutics' Price Target to $5 From $8, Market Outperform Rating Kept	22-08-11	MT
Credit Suisse Lowers eFFECTOR Therapeutics' PT to $10 from $12, Says Funding for Key Readouts In Place; Maintains Outperform Rating	22-08-10	MT
Credit Suisse Lowers eFFECTOR Therapeutics' Price Target to $12 from $14, Keeps Outperform Rating	22-05-11	MT
Credit Suisse Lowers eFFECTOR Therapeutics' Price Target to $14 from $16, Keeps Outperform Rating	22-03-17	MT
Stifel Reinstates Coverage of eFFECTOR Therapeutics With Hold Rating, $4 Price Target	22-03-17	MT
Credit Suisse Lowers eFFECTOR Therapeutics' Price Target to $16 from $20 to Reflect Changes in Tomivosertib Program, Keeps Outperform Rating	22-01-25	MT
Stifel Downgrades EFFECTOR Therapeutics to Hold From Buy, Adjusts Price Target to $6.20 From $20	22-01-25	MT
JMP Securities Adjusts eFFECTOR Therapeutics' Price Target to $8 from $33, Keeps Market Outperform Rating	22-01-25	MT
Stifel Upgrades EFFECTOR Therapeutics to Buy From Hold; Price Target is $20	21-11-09	MT
EFFECTOR THERAPEUTICS : Credit Suisse Starts eFFECTOR Therapeutics at Outperform with $20 PT, Says Current Share Price Offers Attractive Entry Point Ahead of Meaningful Catalysts	21-10-12	MT
EFFECTOR THERAPEUTICS : Credit Suisse Starts eFFECTOR Therapeutics at Outperform With $20 Price Target	21-10-12	MT
EFFECTOR THERAPEUTICS : Mizuho Securities Starts eFFECTOR Therapeutics at Buy With $20 Price Target	21-10-04	MT
EFFECTOR THERAPEUTICS : JMP Securities Starts eFFECTOR Therapeutics at Market Outperform with $33 Price Target	21-09-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Analyst Reco.

Filters